Beximco Pharmaceuticals Statistics

Total Valuation

Beximco Pharmaceuticals has a market cap or net worth of BDT 33.55 billion. The enterprise value is 41.34 billion.

Market Cap	33.55B
Enterprise Value	41.34B

Important Dates

The last earnings date was Monday, January 27, 2025.

Earnings Date	Jan 27, 2025
Ex-Dividend Date	Nov 26, 2024

Share Statistics

Beximco Pharmaceuticals has 446.11 million shares outstanding. The number of shares has decreased by -0.07% in one year.

Current Share Class	n/a
Shares Outstanding	446.11M
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	4.07%
Owned by Institutions (%)	3.86%
Float	311.68M

Valuation Ratios

The trailing PE ratio is 5.28.

PE Ratio	5.28
Forward PE	n/a
PS Ratio	0.72
PB Ratio	0.68
P/TBV Ratio	0.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.90, with an EV/FCF ratio of 17.50.

EV / Earnings	6.51
EV / Sales	0.89
EV / EBITDA	3.90
EV / EBIT	4.70
EV / FCF	17.50

Financial Position

The company has a current ratio of 2.13, with a Debt / Equity ratio of 0.12.

Current Ratio	2.13
Quick Ratio	0.55
Debt / Equity	0.12
Debt / EBITDA	0.58
Debt / FCF	2.62
Interest Coverage	8.48

Financial Efficiency

Return on equity (ROE) is 12.45% and return on invested capital (ROIC) is 9.45%.

Return on Equity (ROE)	12.45%
Return on Assets (ROA)	7.62%
Return on Capital (ROIC)	9.45%
Revenue Per Employee	41.30M
Profits Per Employee	5.66M
Employee Count	1,122
Asset Turnover	0.64
Inventory Turnover	1.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.66% in the last 52 weeks. The beta is 0.66, so Beximco Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	-41.66%
50-Day Moving Average	80.93
200-Day Moving Average	93.15
Relative Strength Index (RSI)	40.23
Average Volume (20 Days)	318,295

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beximco Pharmaceuticals had revenue of BDT 46.34 billion and earned 6.35 billion in profits. Earnings per share was 14.25.

Revenue	46.34B
Gross Profit	20.58B
Operating Income	8.80B
Pretax Income	8.21B
Net Income	6.35B
EBITDA	10.50B
EBIT	8.80B
Earnings Per Share (EPS)	14.25

Full Income Statement

Balance Sheet

The company has 2.36 billion in cash and 6.19 billion in debt, giving a net cash position of -3.84 billion or -8.60 per share.

Cash & Cash Equivalents	2.36B
Total Debt	6.19B
Net Cash	-3.84B
Net Cash Per Share	-8.60
Equity (Book Value)	53.63B
Book Value Per Share	111.31
Working Capital	13.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.90 billion and capital expenditures -2.54 billion, giving a free cash flow of 2.36 billion.

Operating Cash Flow	4.90B
Capital Expenditures	-2.54B
Free Cash Flow	2.36B
FCF Per Share	5.29

Full Cash Flow Statement

Margins

Gross margin is 44.41%, with operating and profit margins of 18.99% and 13.71%.

Gross Margin	44.41%
Operating Margin	18.99%
Pretax Margin	17.73%
Profit Margin	13.71%
EBITDA Margin	22.66%
EBIT Margin	18.99%
FCF Margin	5.10%

Dividends & Yields

This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 5.22%.

Dividend Per Share	4.00
Dividend Yield	5.22%
Dividend Growth (YoY)	14.29%
Years of Dividend Growth	1
Payout Ratio	24.96%
Buyback Yield	0.07%
Shareholder Yield	5.29%
Earnings Yield	18.94%
FCF Yield	7.04%

Dividend Details

Stock Splits

The last stock split was on November 26, 2020. It was a forward split with a ratio of 1.1.

Last Split Date	Nov 26, 2020
Split Type	Forward
Split Ratio	1.1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a